Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/86464
DC FieldValueLanguage
dc.contributor.authorTsai, Hsiao-Chizh_TW
dc.contributor.authorHuang, Chun-Yinzh_TW
dc.contributor.authorSu, Hong-Linzh_TW
dc.contributor.authorTang, Chih-Hsinzh_TW
dc.date2014-
dc.date.accessioned2015-08-04T05:56:59Z-
dc.date.available2015-08-04T05:56:59Z-
dc.identifier.issn01674889zh_TW
dc.identifier.urihttp://hdl.handle.net/11455/86464-
dc.description.abstractOsteosarcoma is the most common primary malignant tumor, and its treatments require more effective therapeutic approaches. Paclitaxel has a broad range of antitumor activities, including apoptosis-inducing effects. However, the majority of tumors in patients with advanced cancer eventually develop chemoresistance. Connective tissue growth factor (CTGF) is a secreted protein that modulates the invasiveness of certain human cancer cells by binding to integrins. However, the effect of CTGF in paclitaxel-mediated chemotherapy is unknown. Here, we report that the expression of CTGF in osteosarcoma patients was significantly higher than that of the CTGF expression in normal bone tissues. Overexpression of CTGF increased the resistance to paclitaxel-mediated cell apoptosis. In contrast, knockdown of CTGF expression by CTGF shRNA increased the chemotherapeutic effect of paclitaxel. In addition, CTGF increased resistance to paclitaxel-induced apoptosis through upregulation of survivin expression. Moreover, the AMP-activated protein kinase (AMPK)-dependent nuclear factor kappa B (NF-κB) pathway mediated paclitaxel-increased chemoresistance and survivin expression. In a mouse xenograft model, overexpression of CTGF promoted resistance to paclitaxel. In contrast, knockdown of CTGF expression increased the therapeutic effect of paclitaxel in this model. In conclusion, our data indicate that CTGF might be a critical oncogene of human osteosarcoma involved in resistance to paclitaxel treatment.zh_TW
dc.language.isoenzh_TW
dc.relationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, Volume 1843, Issue 5, Page(s) 846-854.zh_TW
dc.subjectCTGFzh_TW
dc.subjectChemotherapyzh_TW
dc.subjectOsteosarcomazh_TW
dc.subjectPaclitaxelzh_TW
dc.subjectSurvivinzh_TW
dc.subjectAnimalszh_TW
dc.subjectAntineoplastic Agents, Phytogeniczh_TW
dc.subjectCell Line, Tumorzh_TW
dc.subjectConnective Tissue Growth Factorzh_TW
dc.subjectDrug Resistance, Neoplasmzh_TW
dc.subjectHumanszh_TW
dc.subjectIn Situ Nick-End Labelingzh_TW
dc.subjectInhibitor of Apoptosis Proteinszh_TW
dc.subjectMicezh_TW
dc.subjectMice, Nudezh_TW
dc.subjectOsteosarcomazh_TW
dc.subjectPaclitaxelzh_TW
dc.subjectReal-Time Polymerase Chain Reactionzh_TW
dc.subjectUp-Regulationzh_TW
dc.titleCTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cellszh_TW
dc.typeJournal Articlezh_TW
dc.identifier.doi10.1016/j.bbamcr.2014.01.007zh_TW
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextno fulltext-
item.languageiso639-1en-
item.grantfulltextnone-
Appears in Collections:生命科學系所
Show simple item record
 

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.